RENAL CELL CARCINOMA AREN1721

Study #AREN1721

TFE/tRCC: A Randomized Phase II Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups

Back To Clinical Trials